Fetal microchimeric cells in a fetus-treats-its-mother paradigm do not contribute to dystrophin production in serially parous mdx females.

@article{Seppanen2012FetalMC,
  title={Fetal microchimeric cells in a fetus-treats-its-mother paradigm do not contribute to dystrophin production in serially parous mdx females.},
  author={Elke Jane Seppanen and Samantha Susan Hodgson and Kiarash Khosrotehrani and George Bou-Gharios and Nicholas M Fisk},
  journal={Stem cells and development},
  year={2012},
  volume={21 15},
  pages={2809-16}
}
Throughout every pregnancy, genetically distinct fetal microchimeric stem/progenitor cells (FMCs) engraft in the mother, persist long after delivery, and may home to damaged maternal tissues. Phenotypically normal fetal lymphoid progenitors have been described to develop in immunodeficient mothers in a fetus-treats-its-mother paradigm. Since stem cells contribute to muscle repair, we assessed this paradigm in the mdx mouse model of Duchenne muscular dystrophy. mdx females were bred serially to… CONTINUE READING